Skip to content

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radical Cystectomy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04502095
Enrollment
89
Registered
2020-08-06
Start date
2020-09-02
Completion date
2025-03-13
Last updated
2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection

Brief summary

This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.

Detailed description

PRIMARY OBJECTIVE: I. To determine if the utilization of a prophylactic antibiotic during the postoperative period will decrease the rate of urinary tract infection (UTI) post robot-assisted radical cystectomy. SECONDARY OBJECTIVE: I. To identify pre- and post-operative factors that may be associated with the development of a 90-day UTI following radical cystectomy. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I (ANTIBIOTIC): Patients receive ertapenem Intravenously (IV), levofloxacin, or clindamycin IV at induction per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic. GROUP II (CONTROL): Patients receive ertapenem IV, levofloxacin IV or clindamycin IV at induction per standard of care. After surgery, patients are followed up to 120 days.

Interventions

DRUGClindamycin

Given PO

OTHERDiary

Complete drug diary

DRUGErtapenem

Given PO

DRUGLevofloxacin

Given PO

DRUGNitrofurantoin

Given PO

DRUGTrimethoprim-Sulfamethoxazole

Given PO

Sponsors

Roswell Park Cancer Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any patient that electively chooses to have a cystectomy is eligible to participate in the study. Indications for a person who may undergo a cystectomy include having a diagnosis of muscle-invasive bladder cancer (MIBC) or refractory non-muscle invasive bladder cancer (NMIBC) * Any patient that will electively choose to have a robot-assisted radical cystectomy and is able to provide consent * Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion criteria

* Patients with a history of myasthenia gravis * Patients with a history of QT prolongation or taking other drugs that prolong corrected QTc (QTc) should be excluded * Patients with renal dysfunction, creatinine clearance (mL/min) \< 30 * Pregnant or nursing female participants * Females who receive a fertile sex sparing robot-assisted radical cystectomy (RARC) * Unwilling or unable to follow protocol requirements * Patients who receive a prophylactic antibiotic or antibiotic for any other reason prior to discharge * Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug

Design outcomes

Primary

MeasureTime frameDescription
90-day urinary tract infection (UTI) statusAt 90 days after surgeryWill be treated as dichotomous data and will be summarized by group using frequencies and relative frequencies.

Secondary

MeasureTime frameDescription
Identify pre-operative factors associated with the development of UTIUp to 120 days after surgerystratified logistic regression models (stratified by antibiotic use)
Development of Clostridium difficile (C Diff)up to 120 days after surgeryWill be evaluated in patients who received prophylactic antibiotics.
Infections occurring during antibiotic useUp to 120 days after surgeryTo identify which antibiotic is better suited as a prophylactic, comparisons will be made using two-sided Mann-Whitney U and Fisher's exact tests for continuous and categorical variables, respectively.
Identify post operative factors associated with the development of UTIUp to 120 days after surgerystratified logistic regression models (stratified by antibiotic use)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026